Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K38/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/235947CACB1-DERIVED PEPTIDE, VARIANT OF CACB1-DERIVED PEPTIDE, AND USE THEREOF
WO 26.11.2020
Int.Class A61K 38/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10Peptides having 12 to 20 amino acids
Appl.No PCT/KR2020/006650 Applicant KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION Inventor YOUN, Dong-ho
The present invention relates to a Cacb1-derived peptide, a variant of the Cacb1-derived peptide, a composition for the prevention or treatment of hypertension, and a composition for the relaxation of blood vessels, the compositions comprising same. The Cacb1-derived peptide and the variant of the Cacb1-derived peptide according to the present invention have an excellent blood pressure-lowering effect and fewer side effects, and are easy to manufacture and industrialize, and thus can be effectively used in the development of a novel therapeutic agent for hypertension. In addition, the peptide and the variant thereof have a potential vasodilating effect, and thus are expected to be used as candidate materials for a therapeutic agent for diseases that can be treated or ameliorated by vasodilation, such as angina, prostatic hyperplasia, and erectile dysfunction.
2.20200368312GLYCOPEPTIDE DERIVATIVE COMPOUNDS AND USES THEREOF
US 26.11.2020
Int.Class A61K 38/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
14Peptides containing saccharide radicals; Derivatives thereof
Appl.No 16615232 Applicant Insmed Incorporated Inventor Ryan HECKLER

Provided herein are methods and compositions for the treatment of Gram positive bacterial infections. The infection in some embodiments, is a pulmonary infection. The method for treating the bacterial infection, comprises in one embodiment, administering to a patient in need thereof, a composition comprising an effective amount of a compound a glycopeptide derivative of Formula (I) or (II), or a pharmaceutically acceptable salt of Formula (I) or (II).

3.20200368322METHODS OF IDENTIFYING AND USING AGENTS FOR TREATING DISEASES ASSOCIATED WITH INTESTINAL BARRIER DYSFUNCTION
US 26.11.2020
Int.Class A61K 38/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins
Appl.No 16986473 Applicant Yeda Research and Development Co. Ltd. Inventor Benjamin GEIGER

A method of treating a disease associated with intestinal barrier dysfunction in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which downregulates the amount of glucose in intestinal cells, with the proviso that the disease is not Diabetes or obesity. Other agents for treating diseases associated with intestinal barrier dysfunction are also disclosed.

4.20200370032MODIFICATIONS OF PEPTIDE COMPOSITIONS TO INCREASE STABILITY AND DELIVERY EFFICIENCY
US 26.11.2020
Int.Class C12N 9/96
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
Appl.No 16933749 Applicant KAI PHARMACEUTICALS, INC. Inventor Derek Maclean

The disclosed invention relates to methods of modifying peptide compositions to increase stability and delivery efficiency. Specifically, the disclosed invention relates to methods to increase the stability and delivery efficiency of protein kinase C (PKC) modulatory peptide compositions. A “therapeutic peptide composition” comprises a “carrier peptide” and a “cargo peptide.” A “carrier peptide” is a peptide or amino acid sequence within a peptide that facilitates the cellular uptake of the therapeutic peptide composition. The “cargo peptide” is a PKC modulatory peptide. Peptide modifications to either the carrier peptide, the cargo peptide, or both, which are described herein increase the stability and delivery efficiency of therapeutic peptide compositions by reducing disulfide bond exchange, physical stability, reducing proteolytic degradation, and increasing efficiency of cellular uptake.

5.20200368202METHODS FOR THE TREATMENT OF DISEASES AMELIORATED BY PDE4 INHIBITION USING DOSAGE TITRATION OF APREMILAST
US 26.11.2020
Int.Class A61K 31/4035
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
4035Isoindoles, e.g. phthalimide
Appl.No 16991907 Applicant AMGEN INC. Inventor Robert Day

Methods of treating, managing or preventing diseases ameliorated by inhibiting PDE4 such as psoriasis, ankylosing spondylitis, Behcet's disease, rheumatoid arthritis, atopic dermatitis, Crohn's disease, and ulcerative colitis are disclosed. Specific methods encompass the administration of apremilast in specific dosage titration schedule, alone or in combination with a second active agent.

6.20200368332METHOD OF ENHANCING VIRAL-MEDIATED GENE DELIVERY
US 26.11.2020
Int.Class A61K 38/57
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
55Protease inhibitors
57from animals; from humans
Appl.No 16778558 Applicant WAYNE STATE UNIVERSITY Inventor Zhuo-Hua PAN

The invention provides methods for enhancing the delivery of viral vectors to the eye of a subject by administering a proteasome inhibitor or and a viral vector ending a gene of interest to the eye.

7.WO/2020/234387IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES
WO 26.11.2020
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/EP2020/064132 Applicant CYTUNE PHARMA Inventor MOEBIUS, Ulrich
The present invention provides pulsed cyclic administration regimes and pulsed administration regimes for interleukin-2/interleukin-15 receptor βɣ (IL-2/IL-15Rβɣ) agonists for treating or managing cancer or infectious diseases in human patients. The administration regimes inter alia involve daily administration of IL-2/IL-15Rβɣ agonists on 2, 3 or 4 consecutive days followed by days without administration.
8.WO/2020/233176GROWTH FACTOR SUSTAINED RELEASE MICROSPHERE, TISSUE ENGINEERING CARTILAGE COMPOSITE STENT AND MANUFACTURE METHOD THEREFOR
WO 26.11.2020
Int.Class A61K 9/52
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
52Sustained or differential release type
Appl.No PCT/CN2020/075159 Applicant CHINESE PLA GENERAL HOSPITAL Inventor GUO, Quanyi
Disclosed are a growth factor sustained release microsphere, a tissue engineering cartilage composite stent and a manufacture method therefor. The growth factor sustained release microsphere comprises a polylactic acid-glycolic acid copolymer host material and a recombinant human transforming growth factor β3 encapsulated in the host material, wherein the encapsulation amount of the recombinant human transforming growth factor β3 in the microsphere is 5ng/mg~200ng/mg; the sustained release period of the microsphere is 28 days or more.
9.20200369721CRYSTAL OF REDUCED GLUTATHIONE AND METHOD FOR PRODUCING SAME
US 26.11.2020
Int.Class C07K 5/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
5Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
02containing at least one abnormal peptide link
Appl.No 16988335 Applicant KYOWA HAKKO BIO CO., LTD. Inventor Kazunari FUKUMOTO

The present invention provides a crystal of reduced glutathione having excellent powder properties and a method for producing the same. The present invention relates to a crystal of reduced glutathione, wherein the average crystal thickness is 10 μm or more.

10.20200368311READY-TO-USE BIVALIRUDIN COMPOSITIONS
US 26.11.2020
Int.Class A61K 38/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10Peptides having 12 to 20 amino acids
Appl.No 16417362 Applicant MAIA Pharmaceuticals, Inc. Inventor Srikanth SUNDARAM

Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.